Clinical trials: Reduced Ejection Fraction Heart Failure
Aging, Heart Failure With Preserved Ejection Fraction
Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure
In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage…
- Conditions
- Aging, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Frailty
- Trial name
- RETRO (NCT06576297)
- Testing
- Inspiratory Muscle Training (IMT), Standard of Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pittsburgh
Heart Failure With Reduced Ejection Fraction
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
- Trial name
- NCT05278962
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Heart Failure With Reduced Ejection Fraction, HIV Infections
Heart Failure Polypill at a Safety Net Hospital
A novel four-drug regimen for heart failure with reduced ejection fraction (HFrEF) extends patients' life expectancy by an average of 6 years compared to traditional therapies, in addition to improving quality of life.
- Trial name
- NCT06029712
- Testing
- Heart failure polypill, Control Rx
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had…
- Trial name
- VICTOR (NCT05093933)
- Testing
- Vericiguat
- Where
- 519 sites in United States, Argentina and 34 more
- Volunteers
- 6,106 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation
The concept that direct stimulation of soluble guanylate cyclase (sGC) could be a particularly effective approach to increase cyclic guanosine monophosphate (cGMP) in conditions of increased inflammation/oxidative stress…
- Trial name
- NCT05420012
- Testing
- Vericiguat
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Josef Stehlik
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Heart Failure, Heart Failure, Systolic
Hemodynamic-GUIDEd Management of Heart Failure
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II
- Trial name
- GUIDE-HF (NCT03387813)
- Testing
- CardioMEMS™ HF System
- Where
- 129 sites in United States, Canada
- Volunteers
- 2,358 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Left Bundle-Branch Block
Mid-Q Response Study
The Mid-Q Response study is a prospective, multi-center, randomized controlled, interventional, single-blinded, post-market study.
- Conditions
- Heart Failure, Left Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure NYHA Class II
- Trial name
- NCT04180696
- Testing
- aCRT ON, aCRT OFF
- Where
- 61 sites in Brunei, China and 8 more
- Volunteers
- 177 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in subjects 18 to 80 years of age with HFrEF…
- Trial name
- NCT04210375
- Testing
- JK07
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Salubris Biotherapeutics Inc
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue…
- Trial name
- REALIZE-K (NCT04676646)
- Testing
- Sodium zirconium cyclosilicate, Spironolactone
- Where
- 89 sites in United States, Brazil and 6 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Heart Failure With Reduced Ejection Fraction
Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure
A randomized controlled trial to compare the efficacy of an electronic health record-based alert informing providers about evidence-based medications for HFrEF versus usual care (no alert) in outpatient clinics across a single…
- Trial name
- PROMPT-HF (NCT04514458)
- Testing
- Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)
- Where
- United States
- Volunteers
- 1,410 people
- Sponsor
- Yale University
Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
The recent study is planned to investigate the impact of Ertugliflozin on total burden of ventricular arrhythmias. Further objectives will be number of therapeutic interventions of implanted devices, atrial fibrillation, heart…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy
- Trial name
- ERASE (NCT04600921)
- Testing
- Ertugliflozin 5 mg
- Where
- 8 sites in Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Heart Failure With Reduced Ejection Fraction
Ketone Pharmacokinetic Study in HFrEF
The purpose of this study is to test whether an over-the-counter ketone ester drink is well tolerated in people with heart failure on, and not on, a heart failure medication class called SGLT2 inhibitors.
- Trial name
- NCT05757193
- Testing
- DeltaG (250 mg/kg), DeltaG (500 mg/kg)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Developing Oral LT3 Therapy for Heart Failure - HFrEF
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with reduced ejection fraction (HFrEF) and low triiodothyronine (T3) syndrome…
- Trial name
- DOT3HF-HFrEF (NCT04112316)
- Testing
- Liothyronine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effectiveness of CRD-740 in Heart Failure
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
- Trial name
- CARDINAL-HF (NCT05409183)
- Testing
- CRD-740
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure With Reduced Ejection Fraction
Dashboard Activated Services and Tele-Health for Heart Failure
The Dashboard Activated Services and tele-Health for Heart Failure (DASH-HF) study is a pragmatic randomized controlled trial of a quality improvement (QI) intervention of a prospective panel management intervention to optimize…
- Trial name
- DASH-HF (NCT05001165)
- Testing
- Proactive Panel Management Clinics for HFrEF
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Heart Failure, Heart Failure With Reduced Ejection Fraction
Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF)
Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF) is a pragmatic, cluster-randomized, three-arm intervention trial that will compare the effectiveness of two…
- Trial name
- BETTER CARE-HF (NCT05275920)
- Testing
- Best Practice Alert (BPA), In-Basket Message
- Where
- United States
- Volunteers
- 2,211 people
- Sponsor
- NYU Langone Health
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Acute Heart Failure With Reduced Ejection Fraction
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05139615
- Testing
- APD418
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
Heart Failure With Reduced Ejection Fraction
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv…
- Trial name
- METEORIC-HF (NCT03759392)
- Testing
- Omecamtiv Mecarbil
- Where
- 81 sites in United States, Canada and 7 more
- Volunteers
- 276 people
- Sponsor
- Cytokinetics